Lesson plan

Ralaniten

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It was codiscovered by Dr. Marianne D Sadar and Dr. Raymond J Andersen . It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. It comprises a new pharmacological class recognized by United States Adopted Names (USAN) Council called antigens which are defined as a drug designed to bind to the androgen receptor N-terminal domain. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.

Back to article

Article summary

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It was codiscovered by Dr. Marianne D Sadar and Dr. Raymond J Andersen . It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. It comprises a new pharmacological class recognized by United States Adopted Names (USAN) Council called antigens which are defined as a drug designed to bind to the androgen receptor N-terminal domain. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.